Edgardo Ong
Cardiovascular Disease · Hackettstown, NJNPI 1326199514
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 125 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 19.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,163 and has fallen 98.8% since, to $14 in 2024. That places this record below the midpoint for cardiovascular disease clinicians in NJ, where the typical reported total is $2,633.
Across 125 payments — averaging $17.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$441
- Novo Nordisk$334
- Johnson & Johnson$251
- Amgen$166
- Novartis$150
- Edwards Lifesciences$126
- plus $748 from 19 others
What the payments were for
- Food & beverage$2,210100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 16 | $441 |
| Novo Nordisk | 17 | $334 |
| Johnson & Johnson | 18 | $251 |
| Amgen(2 entities) | 13 | $166 |
| Novartis | 10 | $150 |
| Edwards Lifesciences | 2 | $126 |
| AstraZeneca | 8 | $113 |
| Merck | 8 | $104 |
| Medtronic | 1 | $80 |
| Sanofi-aventis U.S. LLC | 4 | $58 |
| Pfizer | 4 | $56 |
| Kowa Pharmaceuticals America, Inc. | 4 | $55 |
| Amarin Pharma, Inc. | 3 | $41 |
| Esperion Therapeutics, Inc. | 3 | $39 |
| AbbVie | 2 | $29 |
| Biosense Webster, Inc. | 1 | $27 |
| Lilly USA, LLC | 2 | $26 |
| GSK | 2 | $26 |
| Abbott | 1 | $22 |
| Arbor Pharmaceuticals, Inc. | 1 | $16 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $14 |
| Kaleo, Inc. | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
| Regeneron Healthcare Solutions, Inc. | 1 | $13 |
| Bardy Diagnostics, Inc. | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,216 in reported general payments places this provider in the 45th percentile of 1,006 cardiovascular disease providers in New Jersey.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Doxazosin Mesylate | 11 | $300 |
| Atorvastatin Calcium | 20 | $202 |
| Levothyroxine Sodium | 17 | $152 |
| ClopidogrelClopidogrel Bisulfate | 12 | $69 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Hackettstown
- Marc CohenNewark$762K
- Peter FarrugiaColts Neck$600K
- Felix Dailey-SterlingGuttenberg$568K
- Ramzan ZakirNew Brunswick$342K
- Richard KovachBrowns Mills$300K
- Andrea RussoCamden$293K
- John KostisNew Brunswick$225K
- Dilip ViswanathHaddon Heights$167K
- David PowellSpringfield$162K
- Fadi ChaabanWest Orange$161K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.